Takeda Pharmaceutical (TAK) Projected to Announce Earnings on Thursday

Takeda Pharmaceutical (NYSE:TAK) is expected to post its Q1 2027 results before the market opens on Thursday, July 30th. Analysts expect Takeda Pharmaceutical to announce earnings of $0.1689 per share and revenue of $7.1054 billion for the quarter. Individuals can check the company’s upcoming Q1 2027 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 6:00 AM ET.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%.The firm had revenue of $6.90 billion during the quarter. On average, analysts expect Takeda Pharmaceutical to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Takeda Pharmaceutical Price Performance

Shares of TAK opened at $17.57 on Wednesday. The business’s fifty day moving average is $16.21 and its 200 day moving average is $17.06. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $18.90. The company has a quick ratio of 0.60, a current ratio of 1.09 and a debt-to-equity ratio of 0.59. The stock has a market cap of $56.29 billion, a P/E ratio of 45.05 and a beta of -0.07.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, June 23rd. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of hedge funds and other institutional investors have recently modified their holdings of TAK. Parkside Financial Bank & Trust increased its position in shares of Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after acquiring an additional 1,684 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after purchasing an additional 2,328 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares during the period. Advisory Services Network LLC bought a new position in Takeda Pharmaceutical in the 3rd quarter valued at $74,000. Finally, Kestra Advisory Services LLC bought a new position in Takeda Pharmaceutical in the 4th quarter valued at $101,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.